(888) 552-6760 SCHEDULE AN APPOINTMENT

David Luyimbazi,

MD

Attending Surgeon

COH Avatar Physician

The challenge of sitting with each patient and creating a tailored treatment plan demands values I appreciate the most about surgical oncology: compassion, precision, patience, a collaborative team approach and lasting patient-physician relationships.

Location
City of Hope Phoenix
14200 West Celebrate Life Way
Goodyear, AZ 85338
Specialties
General Surgery
Surgical Oncology
Hepato-pancreato-biliary Cancers
Education
Medical school:

New York Medical College – Valhalla, NY

Residency:

General Surgery – University of Connecticut School of Medicine, Farmington, CT

Fellowship:

Post-doctoral Research Fellowship – MD Anderson Cancer Center, Houston, TX
General Complex Surgical Oncology – City of Hope National Medical Center, Duarte, CA

Certifications

General Surgery – American Board of Surgery
General Complex Surgical Oncology – American Board of Surgery

About Me

David Luyimbazi, MD, is an experienced surgical oncologist with expertise in both conventional and minimally invasive procedures. At City of Hope® Cancer Center Phoenix, Dr. Luyimbazi treats a wide range of cancer types, with a particular focus on gastrointestinal and gynecologic cancers that have spread to the abdominal wall cancers, skin cancers, soft tissue tumors and liver and pancreatic cancers.

Dr. Luyimbazi’s approach to cancer care includes collaborating closely with colleagues across multiple specialties to craft a personalized treatment plan for every patient.

“The fundamental role of an oncologist is to shepherd each patient through the process of diagnosis, then to the right treatment and, finally, an acceptable outcome,” he says. “This pathway often ends up being unique to the patient and their values.”

In his clinical work, Dr. Luyimbazi brings extensive expertise in both complex open surgeries, minimally invasive and robotic-assisted procedures for liver, pancreas and biliary tumors and innovative surgical treatments that use intraoperative chemotherapy (or HIPEC).

“Our overall goal remains a sustained chance at a cure. If that is not possible, then we pursue the opportunity to control the disease while providing the patient with an acceptable quality of life for as long as possible,” Dr. Luyimbazi says.

He also works closely with the City of Hope Phoenix team to expand access to breakthrough therapies for patients across the Southwest.

Dr. Luyimbazi earned his medical degree at New York College of Medicine in Valhalla, New York, then went on to complete an internship and residency in general surgery at the University of Connecticut School of Medicine in Farmington. He completed his training with a postdoctoral research fellowship at MD Anderson Cancer Center in Houston, Texas, followed by a complex surgical oncology fellowship at City of Hope National Medical Center in Duarte, California.

A physician-scholar, Dr. Luyimbazi has written or co-authored more than a dozen peer-reviewed articles and presented extensively on his research and clinical practice across the country. He has also received numerous honors, including the Monroe Himelstein, MD, Memorial Award for his dedication to clinical enquiry and teaching excellence during his residency; and recognition in 2024 as one of Virginia’s top doctors in surgical oncology, according to Virginia Business Magazine.

Dr. Luyimbazi is a member of multiple professional organizations, including the Society of Surgical Oncology, the Society of Black Academic Surgeons and the International Hepato-Pancreato-Biliary Association. He has also served in multiple roles for the American College of Surgeons’ Commission on Cancer. In addition to his clinical work at City of Hope Phoenix, Dr. Luyimbazi serves on the clinical faculty within the Department of Surgery at Creighton School of Medicine in Phoenix.

An avid runner and hiker, Dr. Luyimbazi enjoys pursuing these passions in his new home of Arizona.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.